Table 1.
Baseline characteristics
| Group 1 | Group 2 | Group 3 | Total | |
|---|---|---|---|---|
| N | 165 (100%) | 224 (100%) | 173 (100%) | 562 (100%) |
| Gender | ||||
| Male | 115 (70%) | 138 (62%) | 108 (62%) | 361 (64%) |
| Female | 50 (30%) | 86 (38%) | 65 (38%) | 201 (30%) |
| Age | ||||
| Median (range) | 65 (32–84) | 65 (31–88) | 67 (37–87) | 65 (31–88) |
| ECOG PS | ||||
| 0 | 130 (79%) | 124 (55%) | 139 (80%) | 393 (70%) |
| 1 | 32 (19%) | 82 (37%) | 29 (17%) | 143 (25%) |
| 2 | 3 (2%) | 18 (8%) | 5 (3%) | 26 (5%) |
| KRAS mutation status | ||||
| Wild type | 156 (95%) | 216 (96%) | 166 (96%) | 538 (96%) |
| Mutation type | 5 (3%) | 3 (1%) | 6 (3%) | 14 (2%) |
| Not measured | 2 (1%) | 2 (1%) | 1 (1%) | 5 (1%) |
| Unknown | 2 (1%) | 3 (1%) | 5 (1%) | |
| CEA | ||||
| Median (range) | 13 (0.5–8.3 × 103) | 63 (0.7–9.8 × 104) | 27 (0.4–1.0 × 105) | 29 (0.4–1.0 × 105) |
| LDH | ||||
| < ULN | 99 (60%) | 84 (37%) | 107 (62%) | 290 (52%) |
| ≥ULN | 66 (40%) | 140 (63%) | 66 (38%) | 272 (48%) |
| Primary tumor site | ||||
| Colon | 99 (60%) | 154 (69%) | 117 (67%) | 370 (66%) |
| Rectum | 64 (39%) | 67 (30%) | 55 (32%) | 186 (33%) |
| Other | 2 (1%) | 3 (1%) | 1 (1%) | 6 (1%) |
| Resection of primary tumor | ||||
| Yes | 117 (71%) | 102 (46%) | 149 (86%) | 368 (65%) |
| No | 48 (29%) | 122 (54%) | 24 (14%) | 194 (35%) |
CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group scale of performance status.